| Name | AUNP-12 acetate |
| Description | AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity. |
| In vitro | In vitro, AUNP-12 displayed equipotent antagonism toward PD-L1 and PD-L2 in the rescue of lymphocyte proliferation and effector functions. In human PBMC cells, AUNP-12 was also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition in vitro, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively. [1] |
| In vivo | AUNP-12 acetate rescued the proliferation in the mouse splenocyte assay system, with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively. AUNP-12 (6 hours) showed a Plasma protein binding of 93.9% with plasma stability of more than 60%. AUNP-12 exhibited a half-life of 90 minutes in mouse liver microsomes. In male Balb/c mice, AUNP-12 subcutaneous injection or intravenous injection as a concentration of 3 mg/kg for its PK study. As a result, AUNP-12 shows a low volume of distribution, and the peak plasma levels reach at 0.2-0.4 hours. The absolute bioavailability of AUNP-12 is about 77% in mice. [1] |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 25 mg/mL (7.53 mM), Sonification is recommended.
|
| Keywords | AUNP12 acetate | AUNP 12 acetate | 1353563-85-5 Free base | AUNP-12 Acetate | AUNP12 Acetate | AUNP 12 Acetate | 1353563-85-5 |
| Inhibitors Related | LSD1-IN-24 | PD-1/PD-L1-IN-9 | Sulfamethoxypyridazine | PD-1-IN-22 | BMS-202 | BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride | IMMH 010 maleate | LSD1-IN-27 | BMS-1 | PD-L1-IN-3 |
| Related Compound Libraries | Peptide Compound Library | Anti-Cancer Compound Library |
United States
